Amylyx Pharmaceuticals (AMLX) Interest & Investment Income (2021 - 2026)

Amylyx Pharmaceuticals' Interest & Investment Income history runs 6 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 15.19% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $9.6 million (down 17.7% YoY), while the FY2025 annual figure was $9.3 million, down 32.64% from the prior year.
• Interest & Investment Income was $2.6 million for Q1 2026 at Amylyx Pharmaceuticals, down from $3.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.4 million in Q4 2023 to a low of $131000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $2.7 million across 5 years, with a median of $3.1 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 40100.0% in 2022, then plunged 51.83% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $3.2 million in 2022, then soared by 38.45% to $4.4 million in 2023, then plunged by 47.01% to $2.3 million in 2024, then jumped by 42.06% to $3.3 million in 2025, then dropped by 21.88% to $2.6 million in 2026.
• The last three Interest & Investment Income figures came in at $2.6 million (Q1 2026), $3.3 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.